Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group Completes Export of Psilocybin Mushrooms to Canada
Psyence has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company.
Psyence receives MHRA approval for Phase 2 trial
Psyence Group (“Psyence”) has announced formal approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) to commence their highly anticipated Phase 2 trial.
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.